Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT

Lucy C Chappell,1* Jennifer L Bell,2 Anne Smith,2 Catherine Rounding,2 Ursula Bowler,2 Louise Linsell,2 Edmund Juszczak,2 Sue Tohill,1 Amanda Redford,3 Peter H Dixon,1 Jenny Chambers,4 Rachael Hunter,5 Jon Dorling,6 Catherine Williamson1† and Jim G Thornton3†

1Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
2National Perinatal Epidemiology Unit Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
3Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK
4ICP Support, Sutton Coldfield, UK
5Research Department of Primary Care and Population Health, University College London, London, UK
6Division of Neonatal-Perinatal Medicine, IWK Health Centre, Halifax, NS, Canada

*Corresponding author  lucy.chappell@kcl.ac.uk
†Joint senior authors

Declared competing interests of authors: Lucy C Chappell reports that she is chairperson of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Clinical Evaluation and Trials Committee (January 2019 to present), a member of the NIHR Efficacy and Mechanism Evaluation (EME) Strategic Advisory Committee (from November 2019 to present) and is funded by a NIHR Professorship (award number RP-2014-5-019). Jon Dorling reports that he was funded by Nutrinia Ltd. (Ramat Gan, Israel) in 2017 and 2018 for part of his salary to work as an expert advisor on a trial of enteral insulin. Jim G Thornton reports that he is a co-author of the Cochrane review of treatment for obstetric cholestasis, a co-author of a previous trial of ursodeoxycholic acid to treat intrahepatic cholestasis of pregnancy and that he is a member of the NIHR HTA and EME Editorial Board.

Published December 2020
DOI: 10.3310/eme07090
Scientific summary

The PITCHES RCT
Efficacy and Mechanism Evaluation 2020; Vol. 7: No. 9
DOI: 10.3310/eme07090

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Intrahepatic cholestasis of pregnancy, also called obstetric cholestasis, is the most common liver disorder specific to pregnancy. The disease is characterised by maternal pruritus and raised serum bile acid concentrations, with maternal symptoms and abnormal biochemical tests typically resolving post partum. Intrahepatic cholestasis of pregnancy is associated with increased rates of spontaneous and iatrogenic preterm birth, meconium-stained amniotic fluid and neonatal unit admission. Ursodeoxycholic acid, used outside pregnancy to treat primary biliary cholangitis and other hepatobiliary disorders, has also been used as treatment in intrahepatic cholestasis of pregnancy. Ursodeoxycholic acid is recommended in six national guidelines for the management of intrahepatic cholestasis of pregnancy, principally for improvement of maternal symptoms and biochemical tests, and surveys of practice have reported wide usage by obstetricians for treating this disorder. Despite these widespread recommendations for the use of ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy, the evidence base is scant.

Objectives

We set out to address the following research question: ‘Does ursodeoxycholic acid improve perinatal outcome, through a reduction in a composite outcome of perinatal death, prematurity and neonatal unit admission, in women with intrahepatic cholestasis of pregnancy?’.

The main objective of the study was to perform a randomised, placebo-controlled trial of ursodeoxycholic acid in women with intrahepatic cholestasis of pregnancy to determine whether or not ursodeoxycholic acid reduces perinatal death, preterm delivery and neonatal unit admission.

The secondary objective of the study was to collect a biobank of samples to enable mechanistic studies to be undertaken to elucidate the mechanism of action of ursodeoxycholic acid.

Methods

We performed a two-arm, parallel-group, masked, multicentre, randomised placebo-controlled trial with individual randomisation to ursodeoxycholic acid or placebo using a 1 : 1 allocation ratio. A woman was eligible if she had a diagnosis of intrahepatic cholestasis of pregnancy (defined as maternal pruritus with a raised, randomly timed, serum bile acid concentration above the upper limit of normal as measured in the local laboratory), was between 20\text{+0} and 40\text{+6} weeks of pregnancy on day of randomisation (with a singleton or twin pregnancy), had no known lethal fetal anomaly, was aged \geq 18 years, and was able to give written informed consent. A woman was not included in the trial if a decision had already been made for delivery within the next 48 hours, she had any known allergy to any component of the ursodeoxycholic acid or placebo tablets, or if she had a triplet or higher-order multiple pregnancy. We undertook the trial in 33 maternity units in England and Wales. The trial was approved by the East of England – Essex Research Ethics Committee (number 15/EE/0010).

We allocated women to ursodeoxycholic acid or matched placebo tablets, manufactured and supplied by Dr Falk Pharma GmbH (Freiburg im Breisgau, Germany). Each film-coated ursodeoxycholic acid tablet contained the active ingredient, 500 mg of ursodeoxycholic acid, and the inactive ingredients magnesium stearate, polysorbate 80, povidone K25, microcrystalline cellulose, colloidal anhydrous
silica, crospovidone and talc. The matched placebo tablet was identical in colour and shape to the ursodeoxycholic acid tablet and contained the same inactive ingredients.

We recommended that women were started on a dose of two oral tablets per day (equivalent to 500 mg of ursodeoxycholic acid twice per day), increased by a health-care professional in increments of one tablet per day every 3–14 days if there was no biochemical or symptomatic improvement, to a maximum of four tablets per day. In addition, we recommended that treatment should be continued from enrolment until the infant’s birth.

The primary perinatal outcome was prespecified as a composite of perinatal death (defined as in utero fetal death after randomisation or known neonatal death up to 7 days) or preterm delivery (< 37 weeks’ gestation) or neonatal unit admission for at least 4 hours (from infant delivery until hospital discharge). Each infant was counted once within this composite.

Secondary maternal outcomes included maternal serum concentration of bile acids, alanine transaminase (or aspartate transaminase) and maternal itch score. Secondary perinatal outcomes included the components of the primary outcome, mode of delivery, birthweight, birthweight centile, gestational age at delivery, presence of meconium, Apgar score at 5 minutes, umbilical arterial pH at birth and total number of nights in neonatal unit.

For the sample size, we determined that 550 infants of women with intrahepatic cholestasis of pregnancy (275 per group) were required to have a 90% chance of detecting (as significant at the two-sided 5% level) a reduction in the primary outcome measure from 40% in the control group to 27% in the treated group, corresponding to an absolute risk reduction of 13% and a risk ratio of 0.675. We planned to recruit 580 women in total, to allow for the possibility of 5% of infants being lost to follow-up.

Randomisation was performed using a probabilistic minimisation algorithm to ensure approximate balance within the following groups: study centre, gestational age at randomisation (< 34, 34 to < 37, ≥ 37 weeks’ gestation), single versus twin pregnancy and highest serum bile acid concentration prior to randomisation (< 40 µmol/l, ≥ 40 µmol/l).

For allocation concealment, packs containing ursodeoxycholic acid or placebo were produced by a central manufacturing unit and labelled with unique pack identifiers in accordance with a randomly generated sequence.

Research teams at the study sites approached women to confirm eligibility and provided verbal and written information. A trained clinician obtained written informed consent. A research team member entered baseline data on a web-based database at study enrolment and then allocated a pack number using the web-based randomisation. Clinical teams reviewed participants at routine care clinic visits until delivery. Antenatal care, in particular the timing and mode of delivery, was left to the discretion of the responsible clinician. Research teams undertook standard assessment of safety, with reporting of adverse events and serious adverse events following usual governance procedures.

Trial participants, clinical care providers, outcome assessors and data analysts were all masked to allocation.

All analyses followed the intention to treat principle, that is, all randomised women (and infants) were analysed according to the group they were allocated to, irrespective of the treatment they received, if any.
Results

Between 23 December 2015 and 7 August 2018, of 1418 women found to be eligible, we recruited 605 women (43%), including 37 women with a twin pregnancy, across 33 maternity units. A total of 305 women were allocated to the ursodeoxycholic acid group, with data from 304 women (one woman withdrew, with consent to use all data withdrawn) and 322 infants included in the primary outcome analysis. A total of 300 women were allocated to the placebo group, with 300 women analysed (one woman withdrew, with consent to use baseline data but not to collect outcome data) and 318 infants included in the primary outcome analysis. Follow-up to maternal and infant discharge from hospital continued until December 2018. As we recruited ahead of schedule, we continued recruitment up to the number of women who discontinued the intervention or withdrew from the trial (with approval of the funder, sponsor and ethics committee), such that our total number of women recruited (n = 605) included the target sample size (n = 550 women), the number who discontinued the intervention (n = 53) and those who withdrew (n = 2). Recruitment ended after 605 women had been enrolled.

Baseline characteristics were similar between the two groups. At trial enrolment, the groups were well balanced on minimisation factors.

There was no evidence of a significant difference between the groups in the incidence of the primary outcome (perinatal death, preterm delivery or neonatal unit admission for at least 4 hours): 74 (23.0%) infants in the ursodeoxycholic acid group compared with 85 (26.7%) infants in the placebo group experienced the primary outcome (adjusted risk ratio 0.85, 95% confidence interval 0.62 to 1.15; p = 0.279). Similarly, there was no evidence of a significant difference between the groups in the incidence of the individual components of the primary outcome. There were three in utero fetal deaths after randomisation, one in the ursodeoxycholic acid group and two in the placebo group, with two occurring at 35 weeks’ gestation and one at 37 weeks’ gestation.

There was no evidence of a significant difference between the groups in the median gestational age at delivery. The proportion of women having spontaneous vaginal birth or caesarean section was similar in both groups. No evidence of significant differences was seen between groups in the total number of nights in the neonatal unit or the main diagnosis for neonatal unit admission (the latter was not formally tested).

There was evidence of a significant difference between the groups in post-randomisation maternal itch score, which was lower in the ursodeoxycholic acid group: mean difference −5.7 mm (95% confidence interval −9.7 to −1.7 mm; p = 0.005). Serum bile acid concentrations reduced in both groups over time after study enrolment; however, there was evidence of less reduction in serum bile acid concentrations post randomisation in the ursodeoxycholic acid group than in the placebo group (adjusted geometric mean ratio 1.18, 95% confidence interval 1.02 to 1.36; p = 0.030). In contrast, there was evidence of a reduction in serum alanine transaminase concentration post randomisation in the ursodeoxycholic acid group compared with the placebo group (adjusted geometric mean ratio 0.74, 95% CI 0.66 to 0.83; p < 0.001).

Similar numbers of women in both groups discontinued the intervention, 24 (7.9%) in the ursodeoxycholic acid group compared with 29 (9.7%) in the placebo group, with similar numbers of discontinuations across both groups instigated by clinicians and participants. In a prespecified planned sensitivity analysis excluding infants whose mothers took < 90% of the trial medication, a similar proportion of infants experienced the primary outcome: 49 out of 217 (22.6%) infants in the ursodeoxycholic acid group compared with 44 out of 190 (23.2%) infants in the placebo group (adjusted risk ratio 0.91, 95% confidence interval 0.63 to 1.32; p = 0.627).

In prespecified planned subgroup analyses, we found that there was no evidence of a significant interaction of highest bile acid concentration prior to randomisation (stratified as < 40 µmol/l and ≥ 40 µmol/l).
gestational age at randomisation (< 34 weeks’ gestation, ≥ 34 weeks’ gestation), or between singleton and multifetal pregnancy and the incidence of the primary outcome, nor its components, nor important maternal secondary outcomes (itch score and bile acid concentration post randomisation).

In requested post hoc exploratory analyses, the proportion of infants with the primary outcome in mothers with highest serum bile acid concentrations ≥ 100 µmol/l at randomisation were similar: 9 out of 23 infants (39.1%) in the ursodeoxycholic acid group compared with 7 out of 17 (41.2%) in the placebo group. There was also no evidence of a difference in the proportion of women with spontaneous or iatrogenic preterm birth between the groups.

There were eight serious adverse events reported, all of which were considered unrelated to the trial intervention, two in the ursodeoxycholic acid group and six in the placebo group, relating to a range of organ systems. Seventy-three adverse events were reported: 31 in the ursodeoxycholic acid group and 42 in the placebo group. Of note, the same number in each group (n = 10) reported adverse events related to gastrointestinal disturbances.

There was no evidence of a significant difference in total costs (maternal, infant and cost of ursodeoxycholic acid) between the two trial groups: mean £5,420 (standard error £284) in the ursodeoxycholic acid group compared with mean £5,892 (standard error £353) in the placebo group [adjusted difference –£429 (95% confidence interval –£1,235 to £377); adjusted p-value 0.297].

Conclusions

In this clinical trial of ursodeoxycholic acid in women with intrahepatic cholestasis of pregnancy, there is no evidence that it is effective in reducing a composite of adverse perinatal outcomes. Although we have shown that it appears to be safe, it has no clinically meaningful effect on maternal itch symptoms. Ursodeoxycholic acid does not reduce maternal bile acid concentrations. The analysis in women who reported adherence to the intervention reduced the effect size for the primary outcome, and subgroup analyses did not identify any group likely to show a greater response to ursodeoxycholic acid. In subgroups of women identified by higher peak serum bile acid concentration at study enrolment, there was no discernible effect of ursodeoxycholic acid on the primary perinatal outcomes or its components, or on important maternal outcomes. It is unlikely that a biologically plausible and clinically important reduction has been missed. The 5-mm reduction in itch score reported in this trial is unlikely to be seen as clinically useful by many. There was no significant difference in costs.

The strengths of this study include its size – considerably larger than any previous trial identified in the literature. The trial was rigorously conducted, to a prespecified protocol without changes. The study was undertaken in 33 maternity units across England and Wales, and included women representative of the wider pregnancy population in terms of demographics and spectrum of disease. Recruitment occurred within time and target, indicating equipoise and willingness to participate from clinicians and pregnant women.

Limitations include a primary outcome event rate in the control group that was lower than that estimated for the sample size calculation. Although it is theoretically possible that the trial has insufficient power to show a difference, the lack of effect both in the analysis for women who adhered to the intervention and in subgroup analyses in women at greatest risk of the adverse perinatal outcomes (serum bile acid concentrations ≥ 40 µmol/l at enrolment) suggests that this is unlikely.

This trial suggests that there is no strong evidence base for routine use of ursodeoxycholic acid in women with intrahepatic cholestasis of pregnancy for clinically useful amelioration of maternal symptoms or reduction of adverse perinatal outcomes. It is possible that there are selected subgroups not currently identified that may benefit from treatment with ursodeoxycholic acid. As ursodeoxycholic
acid has been the only treatment consistently proposed in guidelines as a disease-modifying drug, there are no other treatments in current widespread use for prevention of the adverse perinatal outcomes associated with the disease. The only intervention that may impact on adverse perinatal outcomes is likely to be appropriately planned delivery. However, the lack of in vivo evidence of benefit should preclude further routine use of ursodeoxycholic acid, even in the absence of harms, outside a research setting, to avoid women being offered an unproven treatment.

**Recommended future research questions**

1. What is the aetiology and pathophysiology of adverse perinatal outcomes, particularly stillbirth, in women with intrahepatic cholestasis of pregnancy and can a greater understanding enable development of an effective treatment to prevent them? Can these adverse perinatal outcomes be predicted with biomarkers?
2. Are there as yet unidentified groups of women who might respond to ursodeoxycholic acid treatment (such as those with or without comorbidities), for reduction of either maternal symptoms or adverse perinatal outcomes?
3. What is the likely pruritogen in intrahepatic cholestasis of pregnancy and can identification enable development of an effective therapeutic treatment to reduce troublesome symptoms of itch?
4. What is the effectiveness of other unlicensed treatments for intrahepatic cholestasis of pregnancy where a signal of efficacy has been observed, including (but not limited to) rifampicin, S-adenosylmethionine, dexamethasone, activated charcoal, guar gum, cholestyramine?

**Trial registration**

The trial was prospectively registered as ISRCTN91918806.

**Funding**

This project is funded by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 7, No. 9. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Efficacy and Mechanism Evaluation Journal
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme
The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report
The research reported in this issue of the journal was funded by the EME programme as project number 12/164/16. The contractual start date was in March 2015. The final report began editorial review in May 2019 and was accepted for publication in March 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by Chappell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor Geoffrey Meads  Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

Editorial contact: journals.library@nihr.ac.uk